Allogene Therapeutics
Clinical trials sponsored by Allogene Therapeutics, explained in plain language.
-
Off-the-Shelf immune cells take on tough lymphomas
Disease control CompletedThis early-phase study tested a new type of cancer treatment called ALLO-501, which uses donor immune cells engineered to attack lymphoma cells. It was given to 50 adults with large B-cell or follicular lymphoma that had come back or stopped responding to standard treatments. The…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
Off-the-Shelf CAR t cells show promise against Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of cancer treatment called ALLO-715, which uses donor immune cells engineered to attack myeloma cells. It was given to 73 adults whose multiple myeloma had returned or stopped responding to at least three prior treatments. The goal was to …
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:59 UTC